GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

zacks.com - 2026-07-14 09:31:09

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propo

gurufocus.com - 2026-07-13 14:00:00

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate.

businesswire.com - 2026-07-13 13:29:00

UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from...

proactiveinvestors.com - 2026-07-13 10:25:00

UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from new chief executive Luke Miels. The bank reiterated its 'neutra'l rating on GSK ahead of results and a capital markets day due on 28 July.

proactiveinvestors.co.uk - 2026-07-13 09:30:06

GSK said on Monday its cancer drug Jemperli met the ​primary goal of a mid-stage trial, with ‌a clinically significant rate of patients showing no detectable signs of cancer for one year or more after treatment for a specific type of ​locally advanced rectal cancer.

reuters.com - 2026-07-13 03:15:11

British drugmaker ​GSK's experimental ‌drug for treating ​patients ​with advanced or ⁠relapsed ​small-cell ​lung cancer showed positive ​results ​in a late-stage ‌trial ⁠on Friday.

reuters.com - 2026-07-10 07:38:49

Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering ​two experimental antibody drugs after both ‌the drug candidates suffered clinical setbacks.

reuters.com - 2026-07-08 17:20:31

Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China ​unit had secured rights to ‌market two respiratory drugs from British company GSK in mainland China.

reuters.com - 2026-07-08 00:52:16

GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its core earnings per share growth will be between 7% and 9% in 2026. In addition to the strong performance of its blockbusters, Nucala, Dovato, and Jemperli, I believe Exdensur could become another meaningful growth driver.

seekingalpha.com - 2026-06-25 09:36:18

Spero Therapeutics, Inc. and partner GSK receive FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, via partnership with GSK. SPRO stands to receive milestone payments and royalties from GSK, with potential annual earnings of ~$50m and upside if Utebzi achieves blockbuster status. Despite a volatile share price and limited pipeline, SPRO's low burn rate and funding runway into 2028 support a 'buy the dip' thesis for risk-tolerant investors.

seekingalpha.com - 2026-06-18 15:41:04

BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.

zacks.com - 2026-06-18 10:55:24

GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.

zacks.com - 2026-06-18 10:01:28

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved for these patients. This app.

businesswire.com - 2026-06-17 16:21:00

CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis1, caused by certain susceptible pathogens2 in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved for these patients. This approval is a result of GSK's development and exclusive global licensing agreement (excluding select Asian territories) with Spero Therapeutics.iv

globenewswire.com - 2026-06-17 12:36:00

The U.S. ​FDA has ‌approved GSK's oral ​antibiotic ​to treat complicated ⁠urinary ​tract infections, ​the regulator said on ​Wednesday, ​giving patients a ‌new ⁠treatment option against drug-resistant ​infections.

reuters.com - 2026-06-17 11:11:40

Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.

zacks.com - 2026-06-16 15:21:19

GSK's momelotinib wins FDA and EMA orphan status for VEXAS syndrome, backed by early evidence. The company advances a phase II/III study.

zacks.com - 2026-06-12 10:56:13

On June 11, 2026, GSK PLC (GSK) shares rose 3.3% to a current price of $52.86. The stock has shown strong momentum over the past year, with a 31.8% increase, an

gurufocus.com - 2026-06-11 18:04:00

Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.

zacks.com - 2026-06-11 14:26:14

The sudden $10.6 billion acquisition of Nuvalent NASDAQ: NUVL by GSK NYSE: GSK violently shatters a lingering mergers and acquisitions (M&A) drought across the mid-cap biotechnology sector.

marketbeat.com - 2026-06-11 12:27:14

GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks ​to fend off competition from bigger rivals AstraZeneca and Roche.

reuters.com - 2026-06-11 02:04:47

GSK plc (GSK) M&A Call Transcript

seekingalpha.com - 2026-06-10 15:52:10

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

businesswire.com - 2026-06-10 11:19:00

GSK PLC's (LSE:GSK, NYSE:GSK) $10.6 billion (£8bn) acquisition of US biotech Nuvalent has achieved something unusual in large pharmaceutical M&A: analysts broadly agree it makes sense. The debate is less about whether the deal is strategically sound and more about how much upside remains after shelling out a chunky amount for two relatively mature assets.

proactiveinvestors.co.uk - 2026-06-10 08:42:27

Thistle Resources (TSX-V:TRCG, OTC:TRCGF) has intersected broad, high-grade gold mineralization at its Middle River Gold Project, the company said...

proactiveinvestors.com - 2026-06-10 06:01:00

Snail Inc (NASDAQ:SNAL) has launched its open-world kingdom-building survival RPG Bellwright on PlayStation and Xbox, extending a title that has surpassed...

proactiveinvestors.com - 2026-06-10 05:46:00

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value...

proactiveinvestors.com - 2026-06-10 05:36:00

Abacus Global Management (NYSE:ABX) has unveiled LifeARC, a proprietary AI-powered platform that generates personalized lifespan models for individuals...

proactiveinvestors.com - 2026-06-10 04:41:00

After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.

wsj.com - 2026-06-09 21:00:00

Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.

zacks.com - 2026-06-09 16:36:09

GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.

zacks.com - 2026-06-09 13:16:08

GSK (GSK) is experiencing a modest uptick in its stock price following the announcement of its acquisition of Nuvalent (NUVL) for $124 per share, totaling $10.6

gurufocus.com - 2026-06-09 12:14:00

Diane King Hall discusses this morning's top moving stocks by highlighting Micron (MU) as it rallies back after Friday's sell-off. She also touches on Wells Fargo raising its ON Semiconductor's (ON) price target to $140 from $115, and GSK's (GSK) new $10.6 billon acquisition of Nuvalent (NUVL).

youtube.com - 2026-06-09 10:30:06

Stock futures are pointing to a higher open Tuesday as the market looks to extend its recovery from last week's losses; President Trump said last night that the U.S. and Iran are close to a "very, very good deal;" OpenAI has confidentially filed with the SEC for an IPO, but said in a statement it doesn't have a timeline for going public; Nuvalent shares are soaring after the drugmaker agreed to be acquired by British pharmaceutical giant GSK; and Vail Resorts shares are down after the company cut its outlook for the second time this year. Here's what you need to know today.

investopedia.com - 2026-06-09 09:31:38

Nuvalent shares catapulted to a record high Tuesday after GSK made an all-cash bid to buy the small biotech company for $10.6 billion.

investors.com - 2026-06-09 09:21:01

Nuvalent Inc (NASDAQ:NUVL) is soaring in premarket trading, up 38.9% to trade at $122.88, after London-based GSK agreed to acquire the cancer drug developer in an all-cash deal valued at approximately $10.6 billion.

schaeffersresearch.com - 2026-06-09 09:12:37

GSK (GSK) has agreed to acquire Nuvalent Inc. (NUVL) in a $10.6 billion cash deal, giving the British pharmaceutical company a bigger foothold in precision onco

gurufocus.com - 2026-06-09 08:20:00

Multiple notable acquisitions hit the market, OpenAI submits IPO documents, and more

fool.com - 2026-06-09 07:30:00

GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can help drive future growth and offset looming patent expirations in its HIV portfolio. The acquisition, announced on Tuesday, will give the British pharmaceutical giant access to three experimental lung cancer treatments, including two candidates currently under review by the US Food and Drug Administration and expected to receive regulatory decisions later this year.

invezz.com - 2026-06-09 07:02:32

GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where the stock traded as of Monday's close.

barrons.com - 2026-06-09 05:56:00

GSK PLC (LSE:GSK, NYSE:GSK) shares fell 3% after it agreed to acquire US biotechnology company Nuvalent (NASDAQ:NUVL) for $10.6 billion (£8.0 billion),...

proactiveinvestors.com - 2026-06-09 05:39:00

The UK's benchmark FTSE 100 index moved lower on Tuesday, pressured by losses in healthcare giant GSK after the company announced plans to acquire shares of US-based drug developer Nuvalent in a deal valued at $10.6 billion. By 0810 GMT, the blue-chip FTSE 100 had slipped 0.3% to 10,341 points.

invezz.com - 2026-06-09 05:13:34

U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.

marketwatch.com - 2026-06-09 03:37:00

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire US biotechnology company Nuvalent for $10.6 billion (£8.0 billion), adding "immediate" new sales growth opportunities, as well as a trio of advanced lung cancer drugs and other assets to boost its oncology pipeline. The FTSE 100 pharmaceuticals group said the deal would contribute to revenue growth from 2027 and be accretive to core operating profit in 2027 and core earnings per share in 2029, including synergies and reprioritisation.

proactiveinvestors.co.uk - 2026-06-09 02:32:23

The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are currently under review by the FDA for approval this year.

wsj.com - 2026-06-09 02:29:00

British ​drugmaker ‌GSK ​on ​Tuesday ⁠agreed ​to ​acquire ​U.S.-listed ​cancer drug ‌developer ⁠Nuvalent ​for $10.6 ​billion.

reuters.com - 2026-06-09 02:04:20

UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for more than $9 billion, according to a Financial Times report. The companies have been in discussions with the aim of finalizing a deal as early as this week.

cnbc.com - 2026-06-09 00:31:52

UK pharmaceutical ​group GSK ‌is in ​talks ​to buy cancer ⁠drugmaker ​Nuvalent for ​more than $9 billion, ​the ​Financial Times reported ‌on ⁠Monday, citing people familiar ​with ​the ⁠matter.

reuters.com - 2026-06-08 21:15:36

Collaboration leverages Engitix's human ECM Platform to identify high-confidence targets for liver fibrosis regression Collaboration leverages Engitix's human ECM Platform to identify high-confidence targets for liver fibrosis regression

globenewswire.com - 2026-06-08 06:16:00